Transcriptional regulation is highly disease and cell-type specific. We performed H3K27ac chromatin immunoprecipitation and transcriptomic sequencing in primary tumors for the four different subtypes of invasive epithelial ovarian cancer (OC). Histotype-specific regulatory elements (REs) were enriched in enhancers (P<0.001). In silico prediction of putative target genes for histotype-specific 
INTRODUCTION
Epithelial ovarian cancer (OC) is a heterogeneous disease, comprising several different histological subtypes that differ in their underlying genetics, biology, clinical characteristics and cellular origins [1] [2] [3] .
The most common subtype is high-grade serous OC (HGSOC), which accounts for around two-thirds of all invasive OCs, and likely arises from fallopian tube secretory epithelial cells 4 . Other subtypes of invasive OC are rarer and include clear cell and endometrioid OCs (CCOC and EnOC), which are strongly associated with the benign precursor lesion endometriosis 5 , and mucinous OC (MOC), which may derive from appendiceal tissues or primordial germ cells 6 .
Molecular analyses of primary OCs have so far focused on characterizing somatic genomic variations in protein-coding genes, and have implicated distinct genetic alterations and biological pathways in the development of each histotype. In HGSOCs, TP53 mutations are ubiquitous 7 ; loss-of-function of DNA double-strand break repair genes (e.g. BRCA1 , BRCA2 ) are also common 8 and predicate a genomic instability phenotype that results in an accumulation of gross structural genomic changes as tumors develop 9 . CCOCs and EnOCs often harbor somatic pathogenic mutations in ARID1A , a member of the SWI/SNF family of chromatin remodelers 10 ; TERT promoter mutations are specific to CCOCs 11 ; and coding mutations and promoter methylation in DNA mismatch repair genes are relatively common in the EnOC subtype 12 . For MOC, alterations in the MAPK pathway are present in ~70% of tumors, with KRAS hotspot mutations (amino acid 12 or 13) the most frequent genetic change 13 .
There is currently a lack of understanding of the role of non-coding mutations in cancer pathogenesis.
Whole genome sequencing (WGS) studies shows that~96% of all somatic mutations identified in primary tumors lie in non-protein coding DNA regions. A proportion of non-coding somatic mutations likely represent functional drivers of cancer disease development 14 , mediating their effects by modifying the function of regulatory elements (REs) that modify the expression of target genes that contribute to neoplastic development. The regulatory architecture of the non-coding genome is highly tissue and cell-type specific 15 . Somatic mutations within disease-specific REs are therefore expected to affect gene expression in a disease specific manner. The goals of the current study are: (1) To characterize the histotype-specific regulatory landscapes of the different OC histotypes; and (2) using WGS data from primary ovarian tumors, to identify frequently mutated REs (FMREs) that may play a role in disease pathogenesis.
RESULTS

Histotype-Specific Epigenomic and Transcriptomic Landscapes of Ovarian Cancers
We characterized the histotype-specific landscapes of active chromatin in primary ovarian tumors using chromatin immunoprecipitation-sequencing (ChIP-seq) for acetylated lysine 27 of histone H3
protein (H3K27ac). H3K27ac ChIP-seq was performed in twenty primary tumors, five each for the different histotypes: HGSOC, CCOC, EnOC and MOC ( Supplementary Table S1 ). Using the ENCODE ChIP-seq processing pipeline and quality control guidelines ( Supplementary Figure S1 ),
we identified a union set of 295,243 non-overlapping ChIP-seq peaks across all tumors, encompassing 11.6% of the genome ( Figure 1a ). ( Figure 1b ).
We performed RNA sequencing (RNA-seq) in nineteen of these tumors. Consistent with H3K27ac
ChIP-seq data, we identified histotype-specific patterns of gene expression for each tumor type.
There were 1,214 differentially expressed genes (DEGs) specific to CCOC, 519 DEGs for HGSOC, ( Figure 1d-f ). WFDC2 encodes for Human Epididymis and promoters, to putative target genes. We calculated all correlations between gene expression and RE activity to identify all gene-RE pairs within topologically associating domains (TAD) (Spearman's rho > 0.4, P<0.05, distance < 500Kbp) ( Figure 1g ) 17 . We use the term 'CREAG' (collection of ' c is -R egulatory E lements A ssociated with a G ene'), to define the collection of predicted enhancers for a gene of interest; a CREAG is conceptually similar to gene 'plexi' 18 . This defined a catalogue of 15,380 RE-gene associations between 6,197 genes and 11,371 REs across all histotypes, with a median of 2.5 enhancers per CREAG ( Figure 1h ) and 1.4 genes per enhancer ( Figure 1i ). We compared enhancer-gene associations with the GeneHancer database to infer target genes for 285,000 human enhancers 19 . Fourteen percent of our predicted enhancer-gene associations were annotated to the same gene in GeneHancer, 2.3 times more than expected by chance (P<0.001). We then mapped all histotype-specific REs to their putative target gene(s) ( Supplementary Table S2 ) and performed pathway enrichment analysis to identify biological mechanisms associated with each histotype ( Figure 1j and Supplementary Figure S4 ). Genes associated with histotype-specific REs function in pathways known to be involved the development of each histotype. Thus, RE-associated genes for CCOC (e.g. AKT2 , ITGA5 , LAMC1 , MET , PPP2R3A and SGK1 ) are involved in PI3K-Akt signaling (P=0.0017) 3, 20, 21 ; and active REs specific to MOCs are associated with genes (e.g. GCNT3 ,
MUC12 , GALNT5 and B3GNT5 ) involved in O-glycan processing (P=0.0001), which may reflect upregulated mucin production and O -glycosylation activity in this histotype 22 . Pathways common across histotypes were associated with cell proliferation and mitosis ( Supplementary Figure S4 ) .
Super-enhancer Landscapes in Ovarian Cancers
Large enhancer domains, termed super-enhancers (SEs) or stretch enhancers 23 , typically regulate genes critical to cell identity. We asked whether histotype-specific SEs were present, and whether these were associated with genes that may contribute to phenotypic heterogeneity in OCs. We 
Somatically Mutated Regulatory Elements in Primary Ovarian Cancers
We HGSOCs for which both WGS and RNA-seq data were available, we found overall that genes were significantly more likely to be overexpressed in samples with RE mutations compared to wild-type samples, i.e., samples without somatic mutations in the RE of interest. For the 2,893 REs harboring at least 1 somatic SNV, 89 genes were significantly overexpressed (FC > 2), and 46 genes were significantly under expressed (FC < 0.5) (p-value<0.05, binomial distribution), indicating enhancer SNVs are more likely to activate rather than repress gene expression ( Figure 3d ). On chromosome 10, we identified a cluster of nine somatic SNVs all located within the KLF6 promoter, part of a common SE in primary OCs ( Figure 3e ). Two variants coincided with a binding site for PAX8 in the promoter defined by H3K27ac-ChIP-seq in OC cell lines 27 . SE activity is associated with KLF6 expression in all OC histotypes, but the SE is only mutated in HGSOC (P=8.2 x 10 -8 ). KLF6 is a
Krüppel-like transcription factor with tumor suppressor functions, and is associated with chemoresponse and prognosis in OC patients 28 .
At the 6p22.1 locus, we identified a cluster of seven somatic SNVs in an enhancer located~9kb centromeric to the HIST1 gene cluster ( Figure 3f ). In our dataset, the activity of this putative 
Gene-centric Analysis of Frequently Mutated Regulatory Elements
We tested the aggregate of somatic mutations in 6,197 CREAGs identified in primary ovarian tumors.
Nine hundred and sixteen genes had a significantly increased mutation burden across multiple REs associated for each gene (P<0.05, Figure 4a- Based on the normalized mutational burden (p-value) and the frequency with which somatic SNVs occur in any of the REs that contribute to a CREAG, the CD47 CREAG (containing 5 REs) is the most significantly associated with OC and contains 22 mutations in 21 patients (P=6.46x10 -6 , Figure 4c ).
Overall, the PAX8 CREAG was the most frequently mutated in HGSOC; 36/169 tumors (21%) harbored a somatic mutation in at least one of three REs in this CREAG (P=0.003) ( Figures 4f-h ).
PAX8 CREAG is also mutated in other cancer types, however, it is only statistically significant in skin cancer, kidney cancer and ovarian cancer ( Figure 4i ). Histotype-specific REs were strongly enriched for putative enhancers. Enhancer depletion was more common than enhancer gain, consistent with previous reports that loss of activity drives cell-type specific identity. A more in-depth analysis of enhancer activity identified around 1,100 'Müllerian' SEs that are common across all OC histotypes. SEs mark genes associated with cell lineage and cell state, in normal and cancer tissues alike 38 . We identified SEs coinciding with genes that encode established biomarkers in OC, highlighting the disease-specific nature of these findings. This included SEs associated with mucin 16 ( MUC16 ) that encodes CA125, and PAX8 . MUC16 /CA125 is a reliable serum marker that is used clinically to aid in the diagnosis of OC and monitor disease progression.
DISCUSSION
PAX8 is a lineage specific TF that is highly expressed in fallopian tube epithelia, a precursor of HGSOC, is amplified in~80% of HGSOCs, and is an essential gene in OC 8, 24 . The PAX8 SE was detected in all OC histotypes and most active in HGSOC and EnOC. A SE proximal to PPP1R3B was unique to CCOC, PPP1R3B was highest expressed in CCOC compared to the other histotypes, and PPP1R3B knockdown in a CCOC model confirmed its role in production of the glycogen-rich cytoplasm that characterizes CCOC. Similarly, we found other histotype-specific SEs which likely regulate genes important for establishing the defining features of each OC histotype. Overall, the data indicate a role for SE landscapes as underlying drivers of ovarian and histotype-specific pathogenesis.
By integrating mutation data from whole genome sequencing (WGS) of ovarian tumors into these analyses we were able to identify somatic mutations that fall into REs to identify candidate noncoding Perhaps the most compelling finding was the convergence of several analyses that underscore the importance of PAX8 regulation in OC development, in particular for the high-grade serous subtype.
We observed a significant clustering of mutations in PAX8-associated upstream enhancers in HGSOCs but in CCOC or EnOC. PAX8-bound enhancers were also significantly mutated in HGSOC, as were enhancers bound by TEAD4, a known PAX8 binding partner 27, 31 , indicating a role for PAX8
as both a target of and mediator of non-coding somatic mutations. We predict that functional somatic mutations in REs alter binding of a sequence-specific DNA-binding protein, such as a TF, which was suggested by the finding of somatic mutations disrupting the TEAD4 motif within a mutated enhancer on chromosome 6. Knockout of the frequently mutated enhancer at 6p22.1 locus, validated a positive association between the activity of the enhancer and ZSCAN16 expression. Further analysis is needed to determine whether there is a direct contact between the RE and ZSCAN16 .
Our studies also identified novel genes and transcription factors in OC pathogenesis that warrant additional functional studies to validate their role in cancer. In addition to PAX8-and TEAD4-bound enhancers, we also identified significantly increased mutation rates in FOXM1 and ESR1 bound regions in HGSOC. Analysis of HGSOC TCGA data indicates FOXM1 is a frequently altered pathway in HGSOC development 8 and ESR1 is expressed in around 80% of HGSOCs. The somatic mutations at these transcription factor binding sites, could affect the binding specificity forming either stronger or weaker binding, altering their downstream pathways.
In conclusion, through the integration of tissue-specific epigenomic and gene expression landscapes for the different histotypes of OC, and somatic mutation data from large scale whole genome sequencing analyses of primary tumors, we have identified non-coding elements that may contribute to OC development. Many of the mutated REs and their associated genes provide novel insights into disease pathogenesis, and the lineage-specific TF PAX8 was identified a central player in the transcriptional dysregulation caused by non-coding somatic SNVs in HGSOCs.
METHODS
For more detailed procedures please refer to the Supplementary Methods .
Tissue ChIP-Seq
All tissues used were collected with informed consent and the approval of the institutional review boards of University of Southern California and Cedars-Sinai Medical Center. Tissue ChIP-Seq was performed as previously described 39 . Chromatin was immunoprecipitated using an anti-H3K27ac antibody (DiAGenode, C15410196, Denville, NJ). Sequencing libraries prepared from enriched DNA using the ThruPLEX-FD Prep Kit (Rubicon Genomics, Ann Arbor, MI) and were sequenced using 75-base pair single reads on the Illumina platform (Illumina, San Diego, CA) at the Dana-Farber
Cancer Institute. The AQUAS pipeline 40 was used to processed all H3K27ac ChIP-Seq data, with histotype-specific regions called using Diffbind 41 .
RNA-Seq
Primary ovarian cancer specimens were homogenized and total RNA was extracted using TRIzol LS (Thermo Fisher Scientific, catalogue number: 10296028). Ribosomal RNA (rRNA) was depleted using 
RE/gene mapping
We calculated the pairwise correlation ( ) of the H3K27ac ChIP-Seq score of a given RE against the r gene expression, in counts per million (CPM), of all genes within the same TAD. For the remaining RE/gene pairs (Bonferroni-adjusted p < 0.05), we computed a transformed correlation value ( ) as a r′ ij function of the distance between the th RE and th gene, as follows:
where is the correlation between the th RE and th gene, and is a weight parameter r ij i j w ij calculated as follows: of probabilities , where is the total length of the pseudo RE, i.e., the sum of the p = 1
widths of all REs and annotated promoters associated to gene . j
Quantifying Gene Expression Changes Associated with RE Mutations
For 89 WGS samples in PCAWG, RNA-Seq was available. Analysis was restricted to genes with at least two mutated samples in the RE overlapping the promoter or an associated RE. For each gene, we calculated the fold change (FC), defined as the ratio of the median gene expression of the gene in the mutated samples (x 1 ) over the median gene expression of the gene in the non-mutated samples (x 2 ). Pathway enrichment analysis was performed using Metascape, using an adjusted p-value cutoff of 0.10. RSPRY1  GDA  HOXA2  HOXA4  PER1  HOXA10  HOXA3  HOXA5  PIM3  TSPAN14  PLXNB2  MIDN  TOB1  CSNK1E  PARD6B  SOCS3  PTPRF  PLXNB1  EPB41L1  PER2  PHLDB1  WWC1  KCNK3  HOXA9  TBL1XR1  SLC12A7  SOX17  MECOM  VWA1  ZFP92  KHSRP  WNT7A  NDRG1  SHANK2  CDYL  HOXD4  HOXD9  MRE11A  SNX24  CD47  DLG3  CTBP1  GALNT14  GSE1  KLF6  SPSB1  TPM4  PAX8  ADCY5  ARFGAP2  BCKDK  GPBP1L1  HPGD  MTX1  SSH2  ZDHHC5  C16orf87  FASTK  UBE2I  ZBBX  FAM24B  ZNF135  HNF4G  PFKP  SEPT9  DAB2IP  NCOR2  EPAS1  MEIS1 HOXD9  GALNT14  CTBP1  SHANK2  SNX24  MRE11A  CDYL  RMDN1   PAX8   1  2  22  20  18  14  13  12  11  10  9  8  7  6  5  4  3  X 
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